Kiniksa Pharmaceuticals International (KNSA) Enterprise Value (2021 - 2025)
Historic Enterprise Value for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to -$529.3 million.
- Kiniksa Pharmaceuticals International's Enterprise Value fell 5116.22% to -$529.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$529.3 million, marking a year-over-year decrease of 5116.22%. This contributed to the annual value of -$243.6 million for FY2024, which is 1805.29% down from last year.
- As of Q3 2025, Kiniksa Pharmaceuticals International's Enterprise Value stood at -$529.3 million, which was down 5116.22% from -$423.5 million recorded in Q2 2025.
- In the past 5 years, Kiniksa Pharmaceuticals International's Enterprise Value ranged from a high of -$182.1 million in Q2 2022 and a low of -$529.3 million during Q3 2025
- Its 5-year average for Enterprise Value is -$289.7 million, with a median of -$283.8 million in 2021.
- As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Enterprise Value soared by 4418.59% in 2022, and later plummeted by 5116.22% in 2025.
- Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Enterprise Value stood at -$182.2 million in 2021, then decreased by 4.61% to -$190.6 million in 2022, then fell by 8.27% to -$206.4 million in 2023, then dropped by 18.05% to -$243.6 million in 2024, then plummeted by 117.28% to -$529.3 million in 2025.
- Its Enterprise Value stands at -$529.3 million for Q3 2025, versus -$423.5 million for Q2 2025 and -$379.5 million for Q1 2025.